Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THERAPY FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WHO PRESENT LATE OR ARE INELIGIBLE FOR REPERFUSION

https://doi.org/10.20996/1819-6446-2010-6-6-888-901

Full Text:

Abstract

Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion.

About the Authors

M. Cohen
Newark Beth Israel Medical Center
United States

Division of Cardiology

201 Lyons Avenue at Osborne Terrace, Newark, New Jersey 07112



C. Boiangiu
Newark Beth Israel Medical Center
United States

Division of Cardiology

201 Lyons Avenue at Osborne Terrace, Newark, New Jersey 07112



M. Abidi

United States

Division of Cardiology

201 Lyons Avenue at Osborne Terrace, Newark, New Jersey 07112



N. S. Chipigina
Newark Beth Israel Medical Center
Russian Federation

translator

 



References

1. Lloyd-Jones D., Adams R., Carnethon M. et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21–181.

2. Mandelzweig L., Battler A., Boyko V. et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27:2285–93.

3. Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College ofCardiology/AmericanHeartAssociation Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society, endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines forthe Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. J Am Coll Cardiol 2008;51:210–47.

4. Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent Stsegment elevation: the Task Force on the Management of STSegment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 008;29:2909–45.

5. Fesmire F.M., Brady W.J., Hahn S. et al. Clinical policy: indications for reperfusion therapy in emergency department patients with suspected acute myocardial infarction. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Reperfusion Therapy in Emergency Department Patients with Suspected Acute Myocardial Infarction. Ann Emerg Med 2006;48:358–83.

6. Eagle K.A., Nallamothu B.K., Mehta R.H. et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 2008;29:609 –17.

7. Heer T., Schiele R., Schneider S. et al. Gender differences in acute myocardial infarction in the era ofreper fusion (the MITRA registry). Am J Cardiol 2002;89:511–7.

8. Hanania G., Cambou J.P., Gueret P. et al. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart 2004;90:1404 –10.

9. Hasdai D., Behar S., Wallentin L. et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: the EuroHeart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190 –201.

10. Zeymer U., Gitt A.K., Jun̈ ger C. et al. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial infarction. Thromb Haemost 2008;99:155– 60.

11. Cohen M., Gensini G.F., Maritz F. et al., on behalf of the TETAMI Investigators. Prospective evaluation of clinical outcomes after acute ST-segment elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108 Suppl 3:14 –21.

12. Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–21.

13. Gibson C.M., Pride Y.B., Frederick P.D. et al. Trends in reperfusion strategies, door-to-needle and doorto-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156: 1035– 44.

14. Yusuf S., Mehta S.R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial.JAMA 2006; 295:1519 –30.

15. Fefer P., Hod H., Hammerman H., Boyko V., Behar S., Matetzky S. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol 2009;103:149 –53.

16. Bainey K.R., Fu Y., Granger C.B. et al. The benefit of angiographic spontaneous reperfusion in STE￾MI: does it extend to diabetics? Heart 2009;16:1331– 6.

17. Bainey K.R., Fu Y., Wagner G.S. et al. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J 2008;156:248 –55.

18. Giugliani R.P., Sabatine M.S., Gibson C.M. et al. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol 2004;11:1362–7.

19. Cohen M., Gensini G.F., Maritz F. et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42:1348 –56.

20. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13–20.

21. Eagle K.A., Goodman S.G., Avezum A., Budaj A., Sullivan C.M., Lopez-Sendon J. Practice variation and missed opportunities forreperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373–7. 22. Cohen M., Gensini G.F., Maritz F. et al. The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction. J Thromb Thrombolysis 2005;19:155– 61.

22. Mehta R.H., Rathore S.S., Radford M.J., Wang Y., Krumholz H.M. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol 2001;38:736–41.

23. Krumholz H.M., Gross C.P., Peterson E.D. et al. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. Am Heart J 2003;146: 839–47.

24. Alexander K.P., Newby L.K., Armstrong P.W. et al. Acute coronary care in the elderly, part II. ST-segment–elevation myocardial infarction.Ascientific statementfor healthcare professionals from theAmericanHeart Association Council on Clinical Cardiology in Collaboration with the Society of Geriatric Cardiology. Circulation 2007;115: 2570 – 89.

25. Antman E.M., Morrow D.A., McCabe C.H. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477– 88.

26. Sinnaeve P.R., Huang Y., Bogaerts K. et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006;152:684.e1–9.

27. Yagi M., Nakao K., Honda T., Tsurumi Y., Kasanuki H. Clinical characteristics and early outcomes of very elderly patients in the reperfusion era. Int J Cardiol 2004;94:41– 6.

28. Grines C.L. A Prospective Randomized Trial of Primary Angioplasty and Thrombolytic Therapy in Elderly Patients With Acute Myocardial Infarction: Senior PAMI. In: Mintz GS, editor. Proceedings of Transcatheter Cardiovascular Therapeutics; October 16–19, 2005; Washington, DC. New York: CRF Publications, 2005.

29. Bueno H., Alonso J.J., Betriu A. et al. Primary angioplasty versus fibrinolysis in the very elderly. The TRIANA study. Paper presented at: ESC Congress, August 31, 2009, Barcelona, Spain.

30. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779–88.

31. Dzavik V., Sleeper L.A., Cocke T.P. et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK trial registry. Eur Heart J 2003;24:828 –37.

32. Valente S., Lazzeri C., Salvadori C. et al. Effectiveness and safety of routine primary angioplasty in patients aged or 85 years with acute myocardial infarction. Circ J 2008;72:67–70.

33. Song X., Chen Y., Pan W., Lu S. Gender based differences in patients with acute coronary syndrome: findings from Chinese Registry of Acute Coronary Events (CRACE). Chin Med J 2007;12:1063– 67.

34. Parker A.B., Naylor C.D., Chong A., Alter D.A. Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction. Can J Cardiol 2006;22:131–9.

35. Balzi D., Barchielli A., Santoro G.M. et al. Management of acute myocardial infarction in the real world: a summary report from the Ami-Florence Italian Registry. Intern Emerg Med 2008;3:109 –15.

36. Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397– 402.

37. LATE Investigators. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993;342:759–66.

38. Ting H.H., Bradley E.H., Wang Y. et al. Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction. Am J Med 2008;121:316 –23.

39. Schmig A., Ndrepepa G., Kastrati A. Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. Eur Heart J 2006;27:1900 –7.

40. Hochman J.S., Lamas G.A., Buller C.E. et al., for the Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355:2395– 407.

41. Erne P., Schoenenberger A.W., Burckhardt D. et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction. JAMA 2007;297:1985–91.

42. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–60.

43. Sarkiss M.G., Yusuf S.W., Warneke C.L. et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007;109:621–7.

44. Zeymer U., Gitt A.K., Junger C. et al. Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006;27:2661– 6.

45. Collins R., MacMahon S., Flather M. et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996;313:652–9.

46. Collins R., Peto R., Baigent C. et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847– 60.

47. Yusuf S., Mehta S.R., Xie C. et al. Effects of reviparin, a low-molecularweight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293:427–35.

48. Oldgren J., Wallentin L., Afzal R. et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008;29:315–23.

49. Thomas D., Giugliano R.P. Management of ST-segment elevation myocardial infarction: comparison of the updated guidelines from North America and Europe. Am Heart J 2009;158:695–705.

50. White H., Simes R., Aylward P. for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855– 63.

51. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147–51. 53. Hurlen M., Abdelnoor M., Smith P. et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969 –74.

52. van Es R.F., Jonker J.J., Verheugt F.W. et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109 –13.

53. First International Study ofInfarct Survival Collaborative Group. Randomised trial ofintravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2:57– 66.

54. Soumerai S.B., McLaughlin T.J., Spiegelman D. et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115–21.

55. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorialtrial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669–85.

56. Gruppo Italiano per lo Studio della Sopravvivenza nell’ infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–22.

57. Ambrosioni E., Borghi C., Magnani B. The effect ofthe angiotensinconverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80 –5.

58. Charpentier S., Sagnes-Raffy C., Cournot M. et al., for the ESTIM Midi-PyrОnОes Investigators. Determinants and prognostic impact of compliance with guidelines in reperfusion therapy for ST-segment elevation myocardial infarction: results from the ESTIM Midi-PyrОnОes Area. Arch Cardiovasc Dis 2009;5:387–96.

59. Juliard J.M., Golmard J.L., Ducrocq G. et al. Universal reperfusion therapy can be implemented: lessons from 20 years of management of patients admitted within 6 hours of symptom onset with STsegment elevation acute myocardial infarction. Arch Cardiovasc Dis 2009;4:259–67.

60. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139–77.

61. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACSTIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374: 29 –38.


For citation:


Cohen M., Boiangiu C., Abidi M., Chipigina N.S. THERAPY FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WHO PRESENT LATE OR ARE INELIGIBLE FOR REPERFUSION. Rational Pharmacotherapy in Cardiology. 2010;6(6):888-901. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-888-901

Views: 240


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)